We are live on ! Find out more
ACOR

Acorda Therapeutics
ACOR

Delisted

ACOR was delisted on the 11th of April, 2024.

Back to rankings

174 hedge funds and large institutions have $1.01B invested in Acorda Therapeutics in 2018 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 53 increasing their positions, 53 reducing their positions, and 24 closing their positions.

New
Increased
Maintained
Reduced
Closed

144% more call options, than puts

Call options by funds: $43.9M | Put options by funds: $18M

0% more first-time investments, than exits

New positions opened: 24 | Existing positions closed: 24

0% more repeat investments, than reductions

Existing positions increased: 53 | Existing positions reduced: 53

1% less funds holding

Funds holding: 175 → 174 (-1)

29% less capital invested

Capital invested by funds: $1.42B → $1.01B (-$408M)

100% less funds holding in top 10

Funds holding in top 10: 1 → 0 (-1)

Holders
174
Holders Change
-1
Holders Change %
-0.57%
% of All Funds
3.98%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
24
Increased
53
Reduced
53
Closed
24
Calls
$43.9M
Puts
$18M
Net Calls
+$25.9M
Net Calls Change
+$35.6M

Top Buyers

1
State Street
State Street
Massachusetts
+$21M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$18.7M
3
Renaissance Technologies
Renaissance Technologies
New York
+$15.3M
4
Bank of America
Bank of America
North Carolina
+$14.5M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$14.1M

Top Sellers

1
BlackRock
BlackRock
New York
-$26.4M
2
PHS
PFM Health Sciences
California
-$23.6M
3
SCM
Scopia Capital Management
New York
-$13.7M
4
Two Sigma Investments
Two Sigma Investments
New York
-$5.07M
5
BBA
Baker Bros. Advisors
New York
-$4.97M
Name Holding Trade Value Shares
Change 		Change in
Stake
TPSF
101
Texas Permanent School Fund
Texas
$487K -$142K -46 -18%
FIM
102
Freedom Investment Management
Connecticut
$465K +$424K +137 New
O
103
OppenheimerFunds
New York
$444K +$279K +90 +92%
PP
104
Paloma Partners
Connecticut
$436K +$573K +185 New
Balyasny Asset Management
105
Balyasny Asset Management
Illinois
$431K +$566K +183 New
MIM
106
MetLife Investment Management
New Jersey
$402K – – –
BCM
107
BlueCrest Capital Management
Jersey
$397K +$180K +58 +53%
Diamond Hill Capital Management
108
Diamond Hill Capital Management
Ohio
$393K +$161K +52 +45%
MSL
109
Mackay Shields LLC
New York
$383K -$27.9K -9 -5%
ASN
110
Advisory Services Network
Georgia
$365K +$480K +155 New
ARTA
111
A.R.T. Advisors
New York
$349K +$458K +148 New
LSERS
112
Louisiana State Employees Retirement System
Louisiana
$342K -$96K -31 -18%
Los Angeles Capital Management
113
Los Angeles Capital Management
California
$322K – – –
BNP Paribas Financial Markets
114
BNP Paribas Financial Markets
France
$316K +$353K +114 +570%
Arrowstreet Capital
115
Arrowstreet Capital
Massachusetts
$310K -$291K -94 -42%
PIM
116
Partner Investment Management
California
$305K -$316K -102 -44%
HCMT
117
Highland Capital Management (Texas)
Texas
$305K – – –
FQ
118
First Quadrant
California
$290K -$341K -110 -47%
MLICM
119
Metropolitan Life Insurance Company (MetLife)
New York
$286K – – –
KAM
120
Kazazian Asset Management
Florida
$284K – – –
AIM
121
Assured Investment Management
New York
$275K -$341K -110 -49%
BPM
122
Bowling Portfolio Management
Ohio
$267K +$350K +113 New
AG
123
Aperio Group
California
$251K -$37.1K -12 -10%
SOADOR
124
State of Alaska Department of Revenue
Alaska
$250K -$68.1K -22 -17%
CI
125
Cigna Investments
Connecticut
$248K -$214K -69 -39%
3 4
5
6 7

ACOR Hedge Fund Activity: Q3 2018 in Review

174 of the 4,374 institutional investors tracked by Wall St. Rank reported a position in Acorda Therapeutics (ACOR) for Q3 2018, worth a combined $1.01B — down 29% from $1.42B a quarter earlier.

Fund positioning in ACOR was balanced in Q3 2018: 24 funds opened new positions, 24 closed out, 53 added to existing stakes and 53 trimmed.

The largest buyer was State Street, adding an estimated $21M. The largest seller was BlackRock, cutting an estimated $26.4M.

  • 174 institutional investors held Acorda Therapeutics (ACOR) as of Q3 2018, down from 175 in Q2 2018.
  • Funds reported $1.01B of Acorda Therapeutics stock for Q3 2018, down 29% quarter-over-quarter.
  • 24 funds opened new Acorda Therapeutics positions in Q3 2018 and 24 closed out, a net change of 0 holders.
  • The largest Acorda Therapeutics buyer in Q3 2018 was State Street, an estimated $21M added.
  • The largest Acorda Therapeutics seller in Q3 2018 was BlackRock, an estimated $26.4M sold.

Based on aggregated 13F filings for Q3 2018.